Evgen Pharma Share Discussion Threads

[tomboyb] 10/11/2021 10:36

Evgen Pharma welcomes research on lead asset in treatment of rare brain cancer

Evgen Pharma PLC (AIM:EVG) hailed the publication of peer-reviewed data which highlights the potential of its lead asset, SFX-01, in treating glioblastoma, an aggressive and often fatal form of brain tumour.

The major takeaway from the article in the academic journal 'Pharmaceuticals' was the statistically significant survival rate seen in animal models where the sulforaphane-based Evgen treatment was used.

The research, which was carried out by Dr Claudio Festuccia and colleagues at the universities of Aquila, Rome and Rieti, Italy, also confirmed the anti-tumour activity of SFX-01 in lab testing.

Chief executive, Dr Huw Jones, welcomed the update, which he said supported the company’s decision to focus on glioblastoma as one of its core programmes.

“Our design work on a phase II study in glioblastoma patients is well advanced and we are discussing the design with a number of prominent UK and European clinical centres,” he added.

“In due course, we hope to contribute a new treatment option for patients with this devastating disease."

Glioblastoma multiforme is an aggressive type of cancer that can occur in the spinal cord as well as the brain. Treatments are rarely curative and are designed to slow disease progression. As such only 5% of patients survive beyond five years, and 25% beyond a year.

US regulators have granted SFX-01 orphan drug designation to treat people with malignant glioma. This affords the formulation additional data protection and can sometimes result in a shorter timeline to market.

SFX-01 is derived from sulforaphane, a compound from nature that Evgen has converted into a fully synthetic, patented drug.

In Sulforadex, the company’s core technology, Evgen has found a method for synthesising and stabilising the naturally occurring compound to a pharmaceutical standard.

[lovewinshatelosses] 10/11/2021 09:54

Did not see the RNS until seeing it mentioned on here! Confused as to why it is not listed in the 'main' place. Anyway, it looks really good news to me and I am pleased to see it has got some approving nods from others more knowledgeable than me on this board as well.
Even before this RNS, I had no plans to sell even my smaller trading tranche below 10p. Hopefully others who feel similarly confident now, will also sit tight and force the MM's to up the bid. As I said before, the 'real' free float must be pretty small. Hopefully after this further piece in the jigsaw, it will get even smaller. GLA.

[ali g2] 10/11/2021 09:34

Annoying RNS not showing on screen? Would have more interest?

[amaretto1] 10/11/2021 09:16

Nothing .... but it's EVG The share price has a mind of its own :-)

[tomboyb] 10/11/2021 09:08

Admittedly sold out for a quick trade into DDDD -

getting back in is more difficult than expected -

[ali g2] 10/11/2021 09:00

"SFX-01 reduced tumour growth substantially and demonstrated statistically significant improved survival."

What more to say!

[tomboyb] 10/11/2021 08:44

NT at 6.6p -

Missed the RNS -

[amaretto1] 10/11/2021 08:41

I'd love to no, what we all hold on here percentage wise....Most of us are LTH So no flash money

[markth126] 10/11/2021 08:39

Im not selling any and reckon I hold 5% of free float

[amaretto1] 10/11/2021 08:33

No one sell a share on here !!! Let's squeeze them :-)

[amaretto1] 10/11/2021 08:31

Gone to NT on 2 platforms Think your right Nobby... caught short ... clowns

[markth126] 10/11/2021 08:25

MM's seem hungry for shares as I can sell 200000 at 6.3 no problem.

[jusjusjus] 10/11/2021 08:21

code 100: I need shares!

[nobbygnome] 10/11/2021 08:14

Yes the MMs are caught and short and desperately trying to stop momentum trading

[rmc100] 10/11/2021 08:13

Is this just stuck on 6 p ?

[luckykids] 10/11/2021 08:10

MM probably no stock and they are just trying to frustrate buyers until demand gives up or fades away with offers of 1000 onlyProbably know Mr Kight won't pay higher so eventually some holders will give up and they can go back to trying to fill big orders for him

[paulboz] 10/11/2021 08:05

Can't buy any with Barclays this morning....

[peanut100] 10/11/2021 08:05

Unchanged is unreal

[moneymunch] 10/11/2021 07:55

Lol...don't get him going David, the Peer Review publication is great news on the back of the FDA Orphan Drug Designation, IND confirmation next which all increases the chances of an early commercial partner. Gl :-)

[david gruen] 10/11/2021 07:47

If our two resident experts MM and Nobby think this is good, then it's good for me. :-)

[moneymunch] 10/11/2021 07:47

Multiple Antitumor Molecular Mechanisms Are Activated by a Fully Synthetic and Stabilized Pharmaceutical Product Delivering the Active Compound Sulforaphane (SFX-01) in Preclinical Model of Human Glioblastoma.

.....


5. Conclusions

In this work, we used in vitro and in vivo experimental models to assess the therapeutic potential of SFX-01 for GBM treatment. Our data suggest that SFN targets ER stress and NRF2, paying as a “master regulator” of the body’s stress response. Secondary but very important effects are the inhibition of HDAC activity especially on class I HDACs and inhibition of STAT3 with reduced activity of NFKB pathways which modulate progression of GBM and induce ROS. So, metabolic, oxidative, and epigenetic modifications are the bases of the different effects of SFN. Our study provided detailed evidence that SFX-01 induced cell death and inhibited the growth of GBM cells and xenografts through the modulation of multiple cell-signaling pathways, demonstrating its potential as a new compound for GBM treatment. SFX-01 was also highly effective in eliminating GSCs through the induction of cell differentiation, compared to the less-malignant astrocyte phenotype. SFX-01 also reduced the vasculogenic properties of GBM cells, thus inhibiting the growth of GBM xenografts in vivo. SFX-01 triggered DNA damage and increased RT-mediated γ-H2Ax expression through the production of ROS. Overall, our preclinical data indicated that the effects of SFX-01 are due to multiple molecular mechanisms, participating in switching off autophagy and switching on apoptosis, which are responsible for SFX-01-mediated cell death.

[markth126] 10/11/2021 07:45

Think Mr Kight will be pleased with this outcome after his recent adding, good timing

[nobbygnome] 10/11/2021 07:28

The fact that they used patient derived cells is highly significant. I am not interested in experiments on tumour cell lines but patient cells are the real deal!

[amaretto1] 10/11/2021 07:20

Substantially .... significantly... are always 2 words you want to see in a Bio RNS ......We have both !!!

[wapper] 10/11/2021 07:19

Excellent news